Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stellar Appoints Tessie Che, Ph.D. to Board of Directors

Published: Thursday, September 26, 2013
Last Updated: Thursday, September 26, 2013
Bookmark and Share
Dr. Che is currently Chair of the Board of Directors of Amaran Biotechnology.

Stellar Biotechnologies, Inc. has announced the appointment of Tessie Mary Che, Ph.D. to the Company’s Board of Directors.

Dr. Tessie Che is currently Chair of the Board of Directors of Amaran Biotechnology, Inc., a private biotech company based in Taiwan. Stellar’s recent US$12 Million Private Placement included a $5 Million investment by Amaran Biotechnology.

“Dr. Che brings to Stellar extensive experience pertinent to our key corporate goals at this high-growth stage,” said Frank Oakes, Stellar President and CEO.

Oakes continued, “She co-founded and successfully led a biopharmaceutical firm from development to commercialization of a new drug product to treat Clostridium difficile. In addition, Dr. Che has extensive scientific and operations acumen, as well as strategic ability transforming research programs and pipelines into high-value business assets.”

“It is my pleasure to join Stellar’s Board of Directors,” said Tessie Mary Che, Ph.D. “Stellar’s proprietary strength in KLH protein manufacturing and its vision to target the active immunotherapy market makes this an impressive company with very high commercial potential.”

Dr. Che co-founded Optimer Pharmaceuticals, Inc. (OPTR:NASDAQ) in 1998 and served over ten years as Optimer’s Chief Operating Officer and Senior Vice President of Corporate Affairs.

During the process development years of Optimer’s flagship drug, DIFICID®, Dr. Che built and led the company’s Chemistry, Manufacturing and Quality Control (CMC) teams through the successful and cost-effective registration and commercialization of DIFICID® in the United States, Canada and Europe in 2011.

Prior to Optimer, Dr. Che’s industrial experience included 20 years in research, management and operations at large companies including Exxon Mobil Corporation, Aventis Pharmaceuticals, Inc., and EniChem S.p.A.

She also served as Vice President, Operations of M and D Precision Science Group, Inc. in 1988 and co-founded Cinogen Pharmaceuticals, Inc. (China) serving as Vice President from 1994 to 1996. Cinogen later became a wholly-owned subsidiary of Pharmanex, Inc., where Dr. Che served as Sr. Director of Quality Assurance and Sourcing.

Dr. Che holds bachelors’ degrees in chemistry from Illinois State University and Fu-Jen Catholic University (Taiwan), a Ph.D. in physical-inorganic chemistry from Brandeis University, and did post-doctoral work at Columbia University. She has authored numerous scientific publications and holds over twenty U.S. patents in material synthesis and applications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
Facility expansion and cultivation innovations ensure supply leadership.
Tuesday, July 23, 2013
Stellar Biotechnologies Presents at Annual 2013 NSF Conference
Poster titled “Megathura crenulata Post Larval Culture - Bottleneck for a Valuable Medical Resources” was presented by Brandon Lincicum.
Friday, July 05, 2013
Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology
The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma vaccine which is currently under development.
Thursday, December 09, 2010
Stellar Biotechnologies Announces Achievement of Milestone in Cooperation with Bayer Innovation
The Company announces collaboration with Bayer Innovation GmbH for the development of a personalized Non-Hodgkin's-Lymphoma vaccine.
Tuesday, September 21, 2010
Stellar Biotechnologies Welcomes Malcolm Gefter, Ph.D. to Corporate and Scientific Advisory Boards
The addition of Malcolm Gefter brings great senior-level directive talent and experience to Company’s corporate board.
Tuesday, July 13, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Uncovering Rhinovirus C Structure
Researchers have determined the structure of rhinovirus C. Their findings may aid the development of antiviral therapies and vaccines.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!